Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 178

1.

Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.

Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A.

Liver Int. 2019 May 13. doi: 10.1111/liv.14135. [Epub ahead of print]

PMID:
31081997
2.

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.

Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H.

J Gastroenterol. 2019 Mar 13. doi: 10.1007/s00535-019-01569-7. [Epub ahead of print]

PMID:
30868245
3.

The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.

Wong K, Ozeki K, Kwong A, Patel BN, Kwo P.

PLoS One. 2018 Dec 28;13(12):e0208233. doi: 10.1371/journal.pone.0208233. eCollection 2018.

4.

Diagnosis and Management of Primary Biliary Cholangitis.

Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM.

Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3.

PMID:
30429590
5.

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.

Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL.

J Viral Hepat. 2019 Mar;26(3):337-349. doi: 10.1111/jvh.13038. Epub 2018 Dec 11.

PMID:
30421537
6.

Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.

Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY.

Am J Transplant. 2019 May;19(5):1380-1387. doi: 10.1111/ajt.15162. Epub 2018 Nov 26.

PMID:
30378723
7.

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment.

Charville GW, Padda SK, Sibley RK, Puthillath A, Kwo PY.

Case Reports Hepatol. 2018 Aug 5;2018:3413592. doi: 10.1155/2018/3413592. eCollection 2018.

8.

Response to Perrella et al.

Kwo PY, Shiffman ML, Bernstein DE.

Am J Gastroenterol. 2018 Aug;113(8):1251-1252. doi: 10.1038/s41395-018-0166-9. Epub 2018 Jun 19. No abstract available.

PMID:
29915397
9.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X.

Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25.

10.

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort.

Kwo P, Fried MW, Reddy KR, Soldevila-Pico C, Khemichian S, Darling J, Zamor PJ, Napoli AA, Anduze-Faris B, Brown RS Jr.

Hepatol Commun. 2018 Feb 27;2(4):354-363. doi: 10.1002/hep4.1156. eCollection 2018 Apr.

11.

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.

Cholankeril G, Gonzalez HC, Satapathy SK, Gonzalez SA, Hu M, Khan MA, Yoo ER, Li AA, Kim D, Nair S, Wong RJ, Kwo PY, Harrison SA, Younossi ZM, Lindor KD, Ahmed A.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):965-973.e2. doi: 10.1016/j.cgh.2017.12.017. Epub 2018 Feb 8.

PMID:
29427734
12.

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ.

N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.

13.

Drug-drug interactions in hepatitis C virus treatment: Do they really matter?

Ahmed A, Lutchman GA, Kwo PY.

Clin Liver Dis (Hoboken). 2017 Nov 30;10(5):111-115. doi: 10.1002/cld.668. eCollection 2017 Nov. Review. No abstract available.

14.

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.

Kwo PY, Shiffman ML, Bernstein DE.

Am J Gastroenterol. 2018 Jan;113(1):2-4. doi: 10.1038/ajg.2017.420. Epub 2017 Nov 14. No abstract available.

PMID:
29134963
15.

The Liver in Oncology.

Dhanasekaran R, Kwo PY.

Clin Liver Dis. 2017 Nov;21(4):697-707. doi: 10.1016/j.cld.2017.06.003. Epub 2017 Jul 26. Review.

PMID:
28987257
16.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ.

Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print]

17.

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment.

Sinclair SM, Jones JK, Miller RK, Greene MF, Kwo PY, Maddrey WC.

Drug Saf. 2017 Dec;40(12):1205-1218. doi: 10.1007/s40264-017-0566-6.

PMID:
28689333
18.

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.

Terrault NA, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, Kwo PY, Agarwal K, Curry MP, Fagiuoli S, Fung JYY, Gane E, Brown KA, Burra P, Charlton M, Pessoa MG, McCaughan GW.

Transplantation. 2017 May;101(5):956-967. doi: 10.1097/TP.0000000000001704. No abstract available.

PMID:
28437388
19.

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.

Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA, Gadano A, Kwo PY, Burra P, Samuel D, Charlton M, Pessoa MG, Berenguer M.

Transplantation. 2017 May;101(5):945-955. doi: 10.1097/TP.0000000000001708. No abstract available.

PMID:
28437387
20.

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.

Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B.

Ann Hepatol. 2017 May - Jun;16(3):375-381. doi: 10.5604/16652681.1235480.

Supplemental Content

Loading ...
Support Center